Abstract: The present invention relates to a process for the manufacture of microporous carbon materials to perform selective separations of nitrogen in gas mixtures such as hydrogen sulfide, carbon dioxide, methane and C2, C3 and C4+ hydrocarbons, with high efficiency, shaped of microspheres or cylinders from copolymers of poly (vinylidene chloride-co-methyl acrylate) with density of 1.3 to 1.85 g/cm·sup·3 or poly (vinylidene chloride-co-vinyl chloride) with density of 1.3 to 1.85 g/cm.sup.3, using two stages. The first stage consists of a surface passivation of the material by chemical attack in a highly alkaline alcohol solution, with the aim of effecting a precarbonization on the surface of the copolymer that during the pyrolysis process is not deformed and gradually develops microporosity. The material of the first stage presents, in the layer, percentages between 55% to 85% carbon, between 5% to 20% oxygen, and between 10% to 40% chlorine.

Abstract: An ergometric treadmill for sport training comprising a screen, a control system and a system configured for collecting, processing, analyzing and visualizing the biomechanical response of a sportsperson while running on the ergometric treadmill; wherein the ergometric treadmill comprises (a) a plurality of MEMS sensors attached by means of supports to the ergometric treadmill connected to a data capture unit; and (b) a data processing unit configured to generate a plurality of parameters related to the physical exercise performed on the ergometric treadmill by a user and synthesize and show, in graphic form, the parameters generated for the user's biofeedback from the treadmill.

Abstract: The present invention refers to a cell suspension comprising at least 90% of CD45RA? memory T cells, characterized in that the memory T cells are derived from blood of convalescent patients recovered from an infection with a respiratory pathogen and have specific lymphocyte antiviral reactivity against its antigens, for use in the treatment of immunocompromised patients suffering from lymphopenia.

Abstract: This disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a combination of therapeutically effective amounts of an isolated population of natural killer (NK) cells, preferably activated and expanded NK (NKAE) cells, and an antibody or an antigen-binding portion thereof that binds specifically to C-X-C Chemokine Receptor 4 (CXCR4) expressed on the surface of a cancer cell.